Drugs That Distort Your ACTH Test Results

Adrenocorticotropic hormone (ACTH), also called corticotropin, is a pituitary peptide hormone measured by blood immunoassay, distinct from the cortisol test that usually accompanies it. A long list of common medications can push a measured ACTH value up or down without any real change in pituitary or adrenal disease status. The useful clinical question is rarely "is this drug on a list of interferences" but rather "does this drug's expected direction of effect match the pattern the clinician is trying to rule in or out." A low ACTH in a patient on chronic opioids or topical steroids does not carry the same diagnostic weight as a low ACTH in a drug-free patient, and treating the two the same way is the most common interpretation error in practice.

What ACTH measures, and why medication history comes first

ACTH is released from the anterior pituitary in a pulsatile, circadian pattern that normally peaks in the early morning and falls to its lowest point around midnight. Its job is to stimulate adrenal cortisol production. The hypothalamic-pituitary-adrenal (HPA) axis works through negative feedback: rising cortisol suppresses further ACTH release, and falling cortisol releases that suppression. Anything that mimics cortisol, blocks its synthesis, blocks its receptor, or destroys the pituitary cells that make ACTH will shift the number independent of the disease the test is meant to detect.

Exogenous glucocorticoid exposure is a well-established and frequently cited cause of test confusion in the Cushing syndrome workup, which is why standard diagnostic guidance calls for excluding it before biochemical testing begins. Confirming this point against the current Endocrine Society Cushing syndrome guideline is recommended before this article is finalized for clinical use, since the specific version and exact wording were not independently verified for this draft.

ACTH is also pre-analytically fragile. It degrades measurably at room temperature within roughly an hour, so a sample that sits on a counter before being spun down can produce a falsely low result that has nothing to do with medications at all. Collection into a pre-chilled EDTA tube with prompt centrifugation and freezing is standard laboratory practice for this hormone.

Exogenous glucocorticoids: the most common distortion

Any form of glucocorticoid taken from outside the body, oral, injectable, inhaled, topical, or intra-articular, can suppress ACTH by substituting for the body's own cortisol in the feedback loop. This is the single most frequent cause of a falsely low ACTH in clinical practice, and it is established pharmacology rather than a contested finding.

Oral prednisone and similar drugs can begin suppressing morning ACTH after a relatively short course at a modest dose, and higher doses act faster. The general pattern, that sustained glucocorticoid exposure produces measurable HPA axis suppression in a substantial share of long-term users, is well documented in the endocrinology literature. The exact dose-response thresholds vary between studies and populations, and any specific percentage attached to a particular dose should be checked against a current systematic review before being used in patient-facing material.

Inhaled corticosteroids are easy for both patients and clinicians to overlook because they are not perceived as systemic drugs. High-dose inhaled fluticasone or budesonide can suppress the HPA axis in a meaningful proportion of adult users, particularly above product-labeled high-dose thresholds. Topical and intra-articular steroids are probably the most frequently missed culprits: a single large-dose intra-articular triamcinolone injection has been reported to suppress morning cortisol and ACTH for several weeks, and high-potency topical steroids applied over large body surface areas have produced adrenal suppression confirmed on stimulation testing.

Practical rule: ask about steroid use in every form, including joint injections, inhalers, nasal sprays, and skin creams, before interpreting an ACTH result. When exposure is confirmed and safe to interrupt, a washout period before testing is standard practice; short-acting oral glucocorticoids typically require on the order of a day, and depot injections require weeks. Abrupt withdrawal after prolonged glucocorticoid use can also produce a rebound rise in ACTH as the suppressed axis reawakens, which is its own diagnostic trap.

Opioids and central ACTH suppression

Chronic opioid use suppresses ACTH through direct inhibition of corticotropin-releasing hormone (CRH) neurons in the hypothalamus. Opioid-induced adrenal insufficiency (OIAI) is a recognized clinical entity, not a rare pharmacologic curiosity, and cross-sectional studies of patients on long-term opioid therapy have found a meaningful minority with morning cortisol and ACTH values low enough to be clinically significant. The effect appears dose-dependent, with higher morphine-equivalent daily doses associated with a greater risk. Methadone, fentanyl, hydromorphone, and oxycodone have all been implicated; buprenorphine, a partial opioid agonist, appears to suppress the axis less, though the evidence base for that distinction is more limited and worth confirming before it is stated as settled.

Decision framework: what to do when a patient on an interfering drug needs ACTH testing

The common thread: before ordering or interpreting an ACTH level, ask whether the patient's current medications would be expected to push the number in the same direction as the diagnosis under consideration, the opposite direction, or an unpredictable direction. If the expected drug effect and the working diagnosis point the same way, the lab value cannot be trusted to confirm that diagnosis on its own.

Estrogen, oral contraceptives, and the cortisol-binding globulin problem

Estrogen-containing oral contraceptives do not directly suppress or stimulate ACTH secretion in a simple way. Instead, estrogen raises hepatic production of cortisol-binding globulin (CBG), which increases total serum cortisol while free (biologically active) cortisol changes much less. The practical problem is interpretive: a clinician who sees a high total cortisol paired with a normal ACTH may wrongly suspect autonomous cortisol secretion when the real explanation is a binding-protein effect.

Standard diagnostic practice for suspected Cushing syndrome calls for stopping estrogen-containing contraceptives for a period, often cited as around six weeks, before biochemical testing when that is feasible. When contraception cannot be interrupted, late-night salivary cortisol or urinary free cortisol are preferred because they reflect the free hormone fraction rather than total protein-bound cortisol. Transdermal estradiol, because it avoids first-pass hepatic metabolism, appears to have a smaller effect on CBG than oral formulations, though patients should not assume this makes transdermal estrogen "safe" to ignore without checking with the ordering clinician.

Drugs that raise ACTH by blocking cortisol synthesis or action

Several drugs used specifically to manage Cushing syndrome or in other clinical contexts inhibit cortisol synthesis, which removes negative feedback on the pituitary and raises ACTH as an expected, mechanistic consequence rather than as a side effect to be alarmed about.

Metyrapone blocks 11-beta-hydroxylase, the final enzyme in cortisol synthesis, and is used both diagnostically (the metyrapone stimulation test) and therapeutically in Cushing syndrome. A rise in ACTH during metyrapone administration in a patient with an intact pituitary is the expected, desired response, not a sign of new disease.

Ketoconazole, at the higher off-label doses sometimes used for Cushing syndrome, inhibits several cytochrome P450 enzymes in the adrenal steroidogenesis pathway and lowers cortisol, again pushing ACTH up through loss of feedback. Levoketoconazole (brand name Recorlev) is an FDA-approved treatment for endogenous Cushing syndrome; readers and clinicians should confirm the current label and approval status at fda.gov, since drug approvals and labeling can change and the exact approval date should be verified rather than assumed.

Etomidate, an intravenous anesthetic, inhibits the same synthesis pathway even at doses used for procedural sedation, and its adrenal-suppressing effect can last several hours after a single dose. In critically ill patients who have recently received etomidate, an ACTH-cortisol pattern that looks like adrenal insufficiency may simply reflect recent drug exposure rather than sepsis-related adrenal failure.

Mitotane, used for adrenocortical carcinoma, destroys adrenal cortex tissue directly. Patients on mitotane predictably develop adrenal insufficiency requiring lifelong glucocorticoid replacement, and elevated ACTH in this setting reflects the intended effect of the drug rather than an incidental interference.

Mifepristone, a glucocorticoid receptor antagonist approved for hyperglycemia associated with Cushing syndrome, blocks cortisol's action at the receptor without lowering cortisol production. Because the pituitary never "sees" the feedback signal, both ACTH and cortisol can rise substantially during treatment. An ACTH level drawn during mifepristone therapy cannot be interpreted using the usual reference framework.

Checkpoint inhibitors and permanent pituitary injury

Immune checkpoint inhibitors, including ipilimumab (anti-CTLA-4) and the PD-1/PD-L1 inhibitors such as nivolumab, pembrolizumab, and atezolizumab, can trigger autoimmune hypophysitis that damages corticotroph cells in the pituitary. The result is typically a low ACTH paired with low cortisol, mimicking secondary adrenal insufficiency rather than primary adrenal disease.

Hypophysitis is a recognized, clinically significant complication of CTLA-4 inhibitor therapy and occurs less often with PD-1/PD-L1 inhibitors alone, with a higher rate reported when the two classes are combined. Oncology treatment protocols generally call for baseline and periodic monitoring of morning cortisol and ACTH during checkpoint inhibitor therapy; the exact monitoring schedule should follow the current oncology guideline in effect for the specific regimen rather than a fixed interval quoted from an older source. Unlike glucocorticoid- or opioid-induced suppression, ACTH deficiency from checkpoint inhibitor hypophysitis is generally considered permanent, because destroyed corticotroph cells do not regenerate, and affected patients typically need lifelong hydrocortisone replacement.

Other drug classes that can shift the number

SSRIs and other psychiatric medications. Serotonin stimulates CRH release, and some antidepressants have been associated with a transient rise in ACTH and cortisol early in treatment that tends to normalize with continued use over subsequent weeks. Atypical antipsychotics have also been linked to HPA axis changes, though the clinical significance for ACTH test interpretation specifically is less well characterized and should be treated as an area of uncertainty rather than an established interference.

Enzyme-inducing anticonvulsants. Phenytoin, carbamazepine, and phenobarbital induce hepatic enzymes that accelerate cortisol metabolism. The resulting drop in circulating cortisol can trigger a compensatory rise in ACTH, and the same enzyme induction accelerates dexamethasone clearance, which is relevant if the patient is also undergoing a dexamethasone suppression test.

Megestrol acetate, a progestin used as an appetite stimulant in oncology and geriatric care, has intrinsic glucocorticoid receptor activity and can suppress the HPA axis in a manner similar to prednisone at sufficient chronic doses. This is worth asking about specifically, since patients and caregivers rarely think of an appetite stimulant as a "steroid."

Timing ACTH testing around interfering medications

There is no universal rule that works for every drug, because some interferences can be safely reversed before testing and others cannot or should not be. A workable approach:

1. Take a complete medication history that explicitly asks about steroid use in every form (pills, injections, inhalers, nasal sprays, joint injections, topical creams), current or recent opioid use, hormonal contraception or replacement therapy, and any cancer immunotherapy.
2. For drugs that can be safely interrupted, do so for a clinically appropriate period before the draw, and confirm that interruption is safe with the prescribing clinician rather than making that decision unilaterally.
3. For drugs that cannot be interrupted, such as opioids in a patient with chronic pain, checkpoint inhibitors during active cancer treatment, or mifepristone during Cushing syndrome management, document the exposure and consider a dynamic test (such as a cosyntropin stimulation test) rather than relying on a single basal ACTH value.
4. Draw the sample fasting, between roughly 7 and 9 AM, in a pre-chilled EDTA tube processed promptly on ice, and record the exact draw time and the timing of the patient's last dose of any interfering medication.

What is established, what is plausible, and what remains uncertain

Established: exogenous glucocorticoids in any form suppress the HPA axis and can lower ACTH; opioids suppress central CRH/ACTH release; drugs that block cortisol synthesis (metyrapone, high-dose ketoconazole, etomidate) or destroy adrenal tissue (mitotane) raise ACTH through loss of negative feedback; checkpoint inhibitors can cause autoimmune hypophysitis with ACTH deficiency; estrogen raises cortisol-binding globulin and distorts total cortisol measurement.

Plausible but requiring case-by-case confirmation: precise dose thresholds and percentage-of-patients-affected figures cited for specific drugs (for example, exact suppression rates for a given inhaled steroid dose, or exact incidence rates for checkpoint inhibitor hypophysitis by regimen) vary across studies and should be checked against current primary literature or guideline documents before being used to counsel an individual patient; buprenorphine's relative safety compared to full opioid agonists regarding HPA suppression; the clinical significance of antipsychotic-associated HPA changes for ACTH interpretation specifically.

Not established from the material reviewed here: that any supplement, lifestyle intervention, or over-the-counter product reliably "lowers" or "raises" ACTH in a clinically meaningful, reproducible way outside of supporting general HPA axis health through sleep, stress management, and consistent routines.

When to seek urgent care

A very low ACTH with symptoms such as severe fatigue, low blood pressure, vomiting, confusion, or collapse can signal acute adrenal insufficiency (adrenal crisis), which is a medical emergency regardless of the suspected cause, medication-related or otherwise. Anyone with these symptoms, especially a patient recently on long-term glucocorticoids who has stopped them abruptly, a patient on checkpoint inhibitor therapy with new severe fatigue or hypotension, or anyone with known adrenal insufficiency who cannot keep down oral medication, should seek emergency evaluation rather than waiting for a scheduled lab result.

A note on the evidence in this article

These ACTH-related phenomena (glucocorticoid negative feedback, opioid suppression of CRH, steroidogenesis inhibitors raising ACTH, checkpoint inhibitor hypophysitis, and estrogen's effect on cortisol-binding globulin) are grounded in established endocrine physiology and pharmacology. Quantitative data regarding incidence rates, medication dose thresholds, and effect percentages could not be confirmed through direct review of primary sources and are therefore presented in general terms rather than as exact figures. Clinical decisions based on this information, such as medication timing before ACTH testing, should be verified with the patient's clinician, the current FDA label for relevant medications (fda.gov), and current Endocrine Society guidance (endocrine.org) rather than used independently.